第二代抗精神病药物奥氮平致代谢失衡的干预措施研究进展

Research progress on the interventions of second-generation antipsychotics Olanzapine-induced metabolism imbalance

奥氮平属于第二代抗精神病药物,已被临床广泛应用,疗效显著。但随着应用时间的推进,临床发现服用奥氮平的患者出现体重增加、糖脂水平异常等代谢失衡的现象较多。药物性代谢失衡不仅是导致心血管疾病发生的危险因素,还会影响到患者的生活质量和用药依从性,导致病程迁延。因此,奥氮平致代谢失衡这一课题备受关注。本文综述了有关该问题的一些国内外干预措施研究进展,以期为临床及机制研究提供参考。

As one of the second-generation antipsychotics, Olanzapine has been widely used in clinic with remarkable curative effect. However, as the application time progressed, it has been found that the incidence of metabolism imbal- ance is relatively higher in patients taking olanzapine, such as weight gain and abnormal levels of glucose and lipid. Drug-induced metabolism imbalance is a risk faetor for cardiovascular disease and could affect the quality of life and patients＇ medication compliance resulting in prolonging the course of disease. Olanzapine-induced metabolism imbal- ance has attracted much attention, and this article reviews the＇domestic and research progress on interventions of this issue with the hope to provide reference for clinical and mechanism research.